Key points from article :
Swiss company Limula raised $6.8 million to further develop their automated platform for making cell and gene therapies, which are currently expensive to produce.
Led by LifeX Ventures, this funding round aims to tackle the complex and costly manufacturing processes that limit these therapies' availability.
Limula's technology combines a bioreactor and centrifuge, simplifying the production process and reducing cell contamination risk.
Their goal is to make these potentially life-changing therapies more affordable and accessible to a wider population.
The funding will help Limula meet manufacturing standards and move from testing to clinical trials and eventually commercial production.
To validate their platform, Limula is collaborating with the San Raffaele Telethon Institute for Gene Therapy in Milan, a leading center for this type of research.
